Inventor · disambiguated record
Gavin Thurston
Also filed as: THURSTON GAVIN
74 granted patents·36 pending applications·856 citations·filing 1999–2025
99Inventor score
Top patents by PatentIndex Score
110 records- 0198US9987500B2Human antibodies to PD-1REGENERON PHARMA·Filed 2015·Granted Jun 5, 2018·126 cites·10 claims
- 0298US9938345B2Human antibodies to PD-L1REGENERON PHARMA·Filed 2015·Granted Apr 10, 2018·37 cites·8 claims
- 0398US9302015B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Apr 5, 2016·82 cites·57 claims
- 0498US9132192B2Anti-EGFR antibodies and uses thereofREGENERON PHARMA·Filed 2013·Granted Sep 15, 2015·72 cites·4 claims
- 0597US10179819B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2016·Granted Jan 15, 2019·25 cites·12 claims
- 0697US7534868B1Human antibodies to human delta like ligand 4REGENERON PHARMA·Filed 2009·Granted May 19, 2009·38 cites·6 claims
- 0797US7488806B2Human antibodies to human delta like ligand 4REGENERON PHARMA·Filed 2008·Granted Feb 10, 2009·41 cites·8 claims
- 0896US11511001B2Radiolabeled anti-LAG3 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2020·Granted Nov 29, 2022·3 cites·7 claims
- 0996US10730944B2Anti-CD8 antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Aug 4, 2020·30 cites·56 claims
- 1096US10358495B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Jul 23, 2019·47 cites·18 claims
- 1195US12077587B2Anti-CD8 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Granted Sep 3, 2024·2 cites·19 claims
- 1295US11525001B2Anti-CD8 antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Dec 13, 2022·5 cites·56 claims
- 1395US11155633B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2018·Granted Oct 26, 2021·9 cites·24 claims
- 1495US8980268B2Methods for treating cancer by administering an anti-Ang-2 antibodyREGENERON PHARMA·Filed 2013·Granted Mar 17, 2015·16 cites·26 claims
- 1595US7919593B2Human antibodies to human delta like ligand 4REGENERON PHARMA·Filed 2007·Granted Apr 5, 2011·25 cites·22 claims
- 1694US12053534B2Radiolabeled anti-PD-L1 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2021·Granted Aug 6, 2024·2 cites·26 claims
- 1794US12054557B2Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancerREGENERON PHARMA·Filed 2021·Granted Aug 6, 2024·4 cites·33 claims
- 1894US8048418B2Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonistsREGENERON PHARMA·Filed 2009·Granted Nov 1, 2011·34 cites·6 claims
- 1993US11117970B2Human antibodies to PD-L1REGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Sep 14, 2021·4 cites·15 claims
- 2093US10550193B2Methods and antibody compositions for tumor treatmentREGENERON PHARMA·Filed 2015·Granted Feb 4, 2020·8 cites·32 claims
- 2193US9475875B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Oct 25, 2016·14 cites·9 claims
- 2291US11129903B2Multispecific antigen-binding molecules and uses thereofREGENERON PHARMA·Filed 2016·Granted Sep 28, 2021·8 cites·30 claims
- 2391US10905784B2Radiolabeled anti-LAG3 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2018·Granted Feb 2, 2021·9 cites·24 claims
- 2491US10736976B2Radiolabeled anti-PD-L1 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·7 cites·6 claims
- 2591US10738124B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·3 cites·27 claims
- 2690US10806780B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Oct 20, 2020·4 cites·17 claims
- 2790US8987420B2High affinity human antibodies to human angiopoietin-2THURSTON GAVIN·Filed 2010·Granted Mar 24, 2015·15 cites·10 claims
- 2889US10737113B2Human antibodies to PD-1REGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·2 cites·18 claims
- 2989US9968674B2Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibodyREGENERON PHARMA·Filed 2014·Granted May 15, 2018·10 cites·16 claims
- 3089US9017670B2Anti-Tie2 antibodies and uses thereofTHURSTON GAVIN·Filed 2012·Granted Apr 28, 2015·10 cites·10 claims
- 3188US11692032B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 4, 2023·3 cites·28 claims
- 3287US11191844B2Multispecific antigen-binding molecules and uses thereofREGENERON PHARMA·Filed 2016·Granted Dec 7, 2021·4 cites·31 claims
- 3387US9545451B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·6 cites·21 claims
- 3487US9546218B2Anti-Tie2 antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Jan 17, 2017·4 cites·12 claims
- 3586US12389889B2Mouse having a humanized cluster of differentiation 47 geneREGENERON PHARMA·Filed 2024·Granted Aug 19, 2025·0 cites·9 claims
- 3686US8840886B2Method of treating cancer with DLL4 antagonist and chemotherapeutic agentREGENERON PHARMA·Filed 2013·Granted Sep 23, 2014·10 cites·5 claims
- 3785US12419282B2Non-human animals expressing humanized CD3 complexREGENERON PHARMA·Filed 2024·Granted Sep 23, 2025·0 cites·20 claims
- 3885US11965161B2Methods and compositions for sensitization of tumor cells to immune therapyREGENERON PHARMA·Filed 2021·Granted Apr 23, 2024·1 cites·45 claims
- 3985US10844137B2Anti-CTLA-4 antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Nov 24, 2020·2 cites·20 claims
- 4085US6455035B1Angiopoietins and methods of use thereofREGENERON PHARMA·Filed 1999·Granted Sep 24, 2002·97 cites·2 claims
- 4184US11958910B2Bispecific antigen binding molecules that bind HER2, and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Apr 16, 2024·1 cites·22 claims
- 4284US11559576B2Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Jan 24, 2023·1 cites·23 claims
- 4384US10939673B2Method of using mouse having a humanized cluster of differentiation 47 geneREGENERON PHARMA·Filed 2018·Granted Mar 9, 2021·1 cites·7 claims
- 4484US9688764B2Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodiesREGENERON PHARMA·Filed 2016·Granted Jun 27, 2017·3 cites·47 claims
- 4584US2025092139A1Human antibodies to pd-l1REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4684US2024316361A1Human Antibodies To PD-1REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4783US2025122307A1Anti-CTLA-4 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4883US2025064913A1Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4982US11434300B2Methods and antibody compositions for tumor treatmentREGENERON PHARMA·Filed 2019·Granted Sep 6, 2022·2 cites·20 claims
- 5082US10683354B2Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cellsREGENERON PHARMA·Filed 2018·Granted Jun 16, 2020·1 cites·26 claims
Showing the top 50 of 110 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Gavin Thurston files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →